Reports Q2 revenue $36.02M, consensus $35.89M. “We have had an exciting start to 2024 with many encouraging milestones that provide the foundation for ongoing commercial success. We are improving the financial efficiency of the business by growing revenues, improving margins, and reducing expenses. Regarding ZYNRELEF, we continue to expand our partnership with CrossLink and progress our regulatory activities in anticipation of a fourth quarter launch of the VAN,” said Craig Collard, CEO.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRTX:
- Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance
- Is HRTX a Buy, Before Earnings?
- Heron Therapeutics management to meet virtually with Needham
- Heron Therapeutics’ Zynrelef included in 2025 Non-Opioid Policy for Pain Relief
- Biotech Alert: Searches spiking for these stocks today
Questions or Comments about the article? Write to editor@tipranks.com